ATE117370T1 - Chimärer antikörper mit spezifität für menschliches tumor-antigen. - Google Patents

Chimärer antikörper mit spezifität für menschliches tumor-antigen.

Info

Publication number
ATE117370T1
ATE117370T1 AT87115769T AT87115769T ATE117370T1 AT E117370 T1 ATE117370 T1 AT E117370T1 AT 87115769 T AT87115769 T AT 87115769T AT 87115769 T AT87115769 T AT 87115769T AT E117370 T1 ATE117370 T1 AT E117370T1
Authority
AT
Austria
Prior art keywords
specificity
chimeric antibody
tumor antigen
human tumor
human
Prior art date
Application number
AT87115769T
Other languages
English (en)
Inventor
Alvin Y Liu
Randy R Robinson
Karl Erik Hellstrom
Ingegerd Hellstrom
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE117370T1 publication Critical patent/ATE117370T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57446—Specifically defined cancers of stomach or intestine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Details Of Garments (AREA)
  • Luminescent Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT87115769T 1986-10-27 1987-10-27 Chimärer antikörper mit spezifität für menschliches tumor-antigen. ATE117370T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US92324486A 1986-10-27 1986-10-27

Publications (1)

Publication Number Publication Date
ATE117370T1 true ATE117370T1 (de) 1995-02-15

Family

ID=25448370

Family Applications (1)

Application Number Title Priority Date Filing Date
AT87115769T ATE117370T1 (de) 1986-10-27 1987-10-27 Chimärer antikörper mit spezifität für menschliches tumor-antigen.

Country Status (17)

Country Link
US (1) US5354847A (de)
EP (1) EP0266663B1 (de)
JP (1) JPH02501886A (de)
AT (1) ATE117370T1 (de)
AU (2) AU626254B2 (de)
DE (1) DE3751004T2 (de)
ES (1) ES2069527T3 (de)
FI (1) FI891984A0 (de)
GR (1) GR3015810T3 (de)
HU (1) HU209154B (de)
IE (1) IE62304B1 (de)
IL (1) IL84285A (de)
NZ (1) NZ222309A (de)
OA (1) OA09115A (de)
PT (1) PT85995B (de)
WO (1) WO1988003145A1 (de)
ZA (1) ZA878044B (de)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5576195A (en) * 1985-11-01 1996-11-19 Xoma Corporation Vectors with pectate lyase signal sequence
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US6893625B1 (en) * 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
IL85035A0 (en) * 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
CA1341235C (en) * 1987-07-24 2001-05-22 Randy R. Robinson Modular assembly of antibody genes, antibodies prepared thereby and use
GB8720833D0 (en) * 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US6710169B2 (en) 1987-10-02 2004-03-23 Genentech, Inc. Adheson variants
US5336603A (en) * 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
WO1990002569A1 (en) * 1988-09-06 1990-03-22 International Genetic Engineering, Inc. Production of chimeric mouse-human antibodies with specificity to human tumor antigens
US5576184A (en) * 1988-09-06 1996-11-19 Xoma Corporation Production of chimeric mouse-human antibodies with specificity to human tumor antigens
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3900534A1 (de) * 1989-01-10 1990-07-12 Boehringer Mannheim Gmbh Diagnostischer nachweis unter verwendung von chimaeren antikoerpern
CA2047244C (en) * 1989-02-24 2002-09-17 Zanetti Maurizio Genetically engineered immunoglobulins
DE3909799A1 (de) * 1989-03-24 1990-09-27 Behringwerke Ag Monoklonale antikoerper (mak) gegen tumorassoziierte antigene, ihre herstellung und verwendung
US5580774A (en) * 1989-07-31 1996-12-03 Eli Lilly And Company Chimeric antibodies directed against a human glycoprotein antigen
US20050196400A1 (en) * 1991-05-06 2005-09-08 Xoma Technology Ltd. Production of chimeric mouse-human antibodies with specificity to human tumor antigens
CA2078539C (en) * 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
US5635177A (en) 1992-01-22 1997-06-03 Genentech, Inc. Protein tyrosine kinase agonist antibodies
US5543499A (en) * 1993-10-29 1996-08-06 Wake Forest University DNA sequence encoding a polypeptide with anti-tumor properties
US5877016A (en) 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
US5817768A (en) * 1995-06-07 1998-10-06 The New York Blood Center, Inc. Monospecific antibodies against a subunit of fibrinogen
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
EP2172478A3 (de) 1997-02-07 2010-07-28 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Aktivitätsabhängiger neurotrophischer Faktor III (ADNF III)
US6946129B1 (en) * 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
EP1438400B1 (de) 2001-10-01 2009-06-17 Dyax Corp. Mehrkettige eukaryontische display-vektoren und deren verwendungen
US7306919B1 (en) 2001-10-31 2007-12-11 Thornthwaite Jerry T Antigen-antibody cancer recognition system
US7332585B2 (en) 2002-04-05 2008-02-19 The Regents Of The California University Bispecific single chain Fv antibody molecules and methods of use thereof
AU2003240005B2 (en) * 2002-06-14 2010-08-12 Takeda Pharmaceutical Company Limited Recombination of nucleic acid library members
AU2003304411A1 (en) 2002-08-01 2005-03-07 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
US20040156846A1 (en) * 2003-02-06 2004-08-12 Triton Biosystems, Inc. Therapy via targeted delivery of nanoscale particles using L6 antibodies
AU2003901511A0 (en) * 2003-03-28 2003-04-17 Bionomics Limited Nucleic acid molecules associated with angiogenesis II
US20110064730A1 (en) * 2003-03-28 2011-03-17 Thomas John Gonda Method of modulating angiogenesis
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
DE60326052D1 (de) * 2003-12-15 2009-03-19 Pasteur Institut Ermittlung des Repertoires von B-Lymphozyten Populationen
WO2005059176A1 (en) * 2003-12-15 2005-06-30 Institut Pasteur Repertoire determination of a lymphocyte b population
WO2006020114A2 (en) 2004-08-04 2006-02-23 Applied Molecular Evolution, Inc. Variant fc regions
NZ555937A (en) 2005-01-27 2009-05-31 Childrens Hosp & Res Ct Oak GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
EP1850866A4 (de) 2005-01-27 2009-07-08 Univ California Monoklonale therapeutische antikörper zur neutralisierung von botulin-neurotoxinen
EP2343320B1 (de) 2005-03-25 2017-10-25 GITR, Inc. Anti-gitr antikörper und ihre verwendung
AU2006249305B2 (en) 2005-05-26 2012-10-18 Genentech, Inc. Humanized anti-CD40 antibodies and their methods of use
AU2006261127B2 (en) 2005-06-17 2012-03-15 Merck Sharp & Dohme Corp. ILT3 binding molecules and uses therefor
AU2007345745C1 (en) 2006-06-19 2013-05-23 Merck Sharp & Dohme Corp. ILT3 binding molecules and uses therefor
US8003761B2 (en) * 2007-01-23 2011-08-23 Hoffmann-La Roche Inc. Cancerous disease modifying antibodies
US20080213170A1 (en) * 2007-01-23 2008-09-04 Young David S F Cancerous Disease Modifying Antibodies
ES2591281T3 (es) 2007-07-12 2016-11-25 Gitr, Inc. Terapias de combinación que emplean moléculas de enlazamiento a GITR
EP2348052A3 (de) 2007-09-17 2011-10-26 The Regents of The University of California Auf Prostatazellen in situ abzielende internalisierende humane monoklonale Antikörper
US8293100B2 (en) 2009-03-13 2012-10-23 Terrasep, Llc Methods and apparatus for centrifugal liquid chromatography
DK2591099T3 (da) 2010-07-09 2021-02-15 Bioverativ Therapeutics Inc Kimære koagulationsfaktorer
ES2678145T3 (es) 2010-08-24 2018-08-09 Abbott Laboratories Anticuerpos específicos contra la proteína del núcleo del VIH y usos de los mismos
EP2717898B1 (de) 2011-06-10 2018-12-19 Bioverativ Therapeutics Inc. Gerinnungsfördernde verbindungen und anwendungsverfahren dafür
US9738707B2 (en) 2011-07-15 2017-08-22 Biogen Ma Inc. Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
CA2860579A1 (en) 2012-01-10 2013-07-18 Biogen Idec Ma Inc. Enhancement of transport of therapeutic molecules across the blood brain barrier
WO2014089177A2 (en) 2012-12-04 2014-06-12 Massachusetts Institute Of Technology Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
WO2014093417A1 (en) 2012-12-12 2014-06-19 University Of Virginia Patent Foundation Compositions and methods for regulating erythropoiesis
US11046975B2 (en) * 2013-10-07 2021-06-29 Prestige Biopharma Pte. Ltd. Bicistronic expression vector for antibody expression and method for producing antibody using same
US10584147B2 (en) 2013-11-08 2020-03-10 Biovertiv Therapeutics Inc. Procoagulant fusion compound
JP6983779B2 (ja) 2015-11-30 2021-12-17 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California 非常に特異的な腫瘍細胞表面抗原を標的とするヒト抗体を用いた腫瘍特異的ペイロード送達及び免疫活性化
US10995126B2 (en) 2016-05-04 2021-05-04 National Health Research Institutes Immunogenic peptide containing a b cell epitope of tumor associated antigen L6
WO2017197045A1 (en) 2016-05-11 2017-11-16 Movassaghi Mohammad Convergent and enantioselective total synthesis of communesin analogs
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
EP3655031A1 (de) 2017-07-21 2020-05-27 The U.S.A. as represented by the Secretary, Department of Health and Human Services Immunogene zusammensetzungen gegen neisseria meningitidis
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
MA50102A (fr) 2017-11-14 2020-07-15 Univ Virginia Patent Foundation Compositions et méthodes de fabrication et d'utilisation d'anticorps bispécifiques
KR20230066149A (ko) 2020-08-07 2023-05-12 포티스 테라퓨틱스, 인크. Cd46을 표적화하는 면역접합체 및 이의 사용 방법

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4468464A (en) * 1974-11-04 1984-08-28 The Board Of Trustees Of The Leland Stanford Junior University Biologically functional molecular chimeras
US4486538A (en) * 1978-07-07 1984-12-04 Samuel Bogoch Detection of malignant tumor cells
US4650756A (en) * 1981-08-31 1987-03-17 Sloan Kettering Institute For Cancer Research Monoclonal antibodies to cell surface antigens of human renal cancer
US4476538A (en) * 1982-02-01 1984-10-09 Analog Devices, Inc. Trigonometric function generator
ES8407097A1 (es) * 1982-05-12 1984-08-16 Harvard College Un procedimiento para obtener una proteina hibrida.
US4708862A (en) * 1983-02-22 1987-11-24 Xoma Corporation Radioimmuno detection of human cancers using anti-tumor monoclonal antibody
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4550756A (en) * 1984-01-16 1985-11-05 The Goodyear Tire & Rubber Company Pneumatic tire tread
JPS6147500A (ja) * 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (de) * 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimäre Rezeptoren durch Verbindung und Expression von DNS
GB8422238D0 (en) * 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) * 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4906562A (en) * 1984-12-21 1990-03-06 Oncogen Monocolonal antibodies and antigen for human non-small cell lung carcinomas
US4770993A (en) * 1985-10-31 1988-09-13 Beatrice Companies, Inc. Hybridoma tumor cell lines and their monoclonal antibodies to thaumatin
JPS63501765A (ja) * 1985-11-01 1988-07-21 インタ−ナショナル、ジェネティック、エンジニアリング　インコ−ポレ−テッド 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途
US5091178A (en) * 1986-02-21 1992-02-25 Oncogen Tumor therapy with biologically active anti-tumor antibodies

Also Published As

Publication number Publication date
NZ222309A (en) 1990-02-26
ES2069527T3 (es) 1995-05-16
HU209154B (en) 1994-03-28
OA09115A (en) 1991-10-31
AU626254B2 (en) 1992-07-30
JPH02501886A (ja) 1990-06-28
HUT52153A (en) 1990-06-28
PT85995A (en) 1987-11-01
DE3751004T2 (de) 1995-05-24
FI891984A (fi) 1989-04-26
AU8326187A (en) 1988-05-25
PT85995B (pt) 1990-08-31
AU2810592A (en) 1993-01-28
IL84285A0 (en) 1988-03-31
FI891984A0 (fi) 1989-04-26
AU656633B2 (en) 1995-02-09
WO1988003145A1 (en) 1988-05-05
US5354847A (en) 1994-10-11
IE872880L (en) 1988-04-27
GR3015810T3 (en) 1995-07-31
ZA878044B (en) 1988-04-25
DE3751004D1 (de) 1995-03-02
EP0266663A1 (de) 1988-05-11
IE62304B1 (en) 1995-01-25
EP0266663B1 (de) 1995-01-18
IL84285A (en) 1993-03-15

Similar Documents

Publication Publication Date Title
ATE117370T1 (de) Chimärer antikörper mit spezifität für menschliches tumor-antigen.
ES2146572T3 (es) Elementos de expresion genica y la produccion de anticuerpos quimericos de raton-ser humano.
NO861577L (no) Antigen, antistoff og fremgangsmaate for dets fremstilling og anvendelse derav for diagnostisering.
EP0404003A3 (de) Chimäre Maus-Mensch-KM10-Antikörper, spezifisch für ein menschliches Tumorzellen-Antigen
EP0338395A3 (en) Monoclonal antibodies to pseudomonas aeruginosa, their production and use
DE3579808D1 (de) Anti-urokinase monoklonaler antikoerper, seine herstellung und verwendung.
ATE86261T1 (de) Tumorassoziiertes antigen.
ATE92081T1 (de) Tumorassoziiertes antigen.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee